ATHA Athira Pharma, Inc. Stock Quote

ATHA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.72	Insider Own	0.70%	Shs Outstand	37.59M	Perf Week	-66.98%
Market Cap	105.38M	Forward P/E	-	EPS next Y	-3.24	Insider Trans	-4.34%	Shs Float	35.77M	Perf Month	-68.47%
Income	-67.00M	PEG	-	EPS next Q	-0.64	Inst Own	75.40%	Short Float	8.22%	Perf Quarter	-78.36%
Sales	-	P/S	-	EPS this Y	-141.90%	Inst Trans	7.08%	Short Ratio	3.71	Perf Half Y	-77.93%
Book/sh	8.03	P/B	0.35	EPS next Y	-26.50%	ROA	-19.80%	Target Price	11.00	Perf Year	-73.80%
Cash/sh	6.98	P/C	0.40	EPS next 5Y	-	ROE	-20.40%	52W Range	2.53 - 16.65	Perf YTD	-78.59%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-83.24%	Beta	-
Dividend %	-	Quick Ratio	28.40	Sales past 5Y	-	Gross Margin	-	52W Low	10.28%	ATR	0.76
Employees	34	Current Ratio	28.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	16.92	Volatility	11.71% 7.64%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-125.20%	Profit Margin	-	Rel Volume	2.52	Prev Close	2.85
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	793.03K	Price	2.79
Recom	1.70	SMA20	-62.84%	SMA50	-68.73%	SMA200	-74.30%	Volume	1,950,693	Change	-2.11%

Jun-23-22

Downgrade

Stifel

Buy → Hold

$36 → $5

Jun-23-22

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Jun-23-22

Downgrade

Jefferies

Buy → Hold

$32 → $3

May-10-22

Initiated

BTIG Research

Buy

$33

Apr-21-22

Initiated

Berenberg

Buy

$33

Dec-15-21

Initiated

Goldman

Neutral

$16

Oct-13-20

Initiated

Stifel

Buy

$36

Oct-13-20

Initiated

JMP Securities

Mkt Outperform

$51

Oct-13-20

Initiated

Jefferies

Buy

$30

Oct-13-20

Initiated

Goldman

Buy

$53

Jun-22-22 04:49PM	Athira Pharma's stock plummets after disappointing drug trial results American City Business Journals -66.27%
01:29PM	Athira Pharma stock loses two-thirds of its value after study of Alzheimer's treatment misses primary endpoint MarketWatch
11:31AM	Why Athira Pharma Stock Imploded Today Motley Fool
08:25AM	Athira says its Alzheimer's treatment did not meet endpoint in mid-stage trial; stock falls 68% MarketWatch
08:21AM	Athira Pharma Shares Fall To 52-Week Low - Read Why Benzinga
07:00AM	Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimers Disease GlobeNewswire
Jun-07-22 07:00AM	Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research GlobeNewswire
May-22-22 10:43AM	What Kind Of Investors Own Most Of Athira Pharma, Inc. (NASDAQ:ATHA)? Simply Wall St.
May-19-22 12:06PM	Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting GlobeNewswire
May-17-22 05:39AM	Athira shareholder suspends push for board control days before shareholders' meeting American City Business Journals
May-16-22 04:49PM	Athira Issues Statement in Response to Richard A. Kaynes Suspension of His Proxy Contest GlobeNewswire
07:00AM	Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting GlobeNewswire
May-12-22 04:05PM	Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates GlobeNewswire -5.46%
May-11-22 04:15PM	Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting GlobeNewswire -9.17%
May-09-22 07:00AM	Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimers Disease GlobeNewswire
May-05-22 12:04PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote FOR All of Athiras Highly Qualified Director Nominees GlobeNewswire -6.29%
08:00AM	Athira Mails Letter to Shareholders Emphasizing the Companys Strong Position and Qualified Board as it Enters Pivotal Chapter GlobeNewswire
May-04-22 06:46PM	Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athiras WHITE Proxy Card GlobeNewswire
Apr-28-22 12:54AM	Athira leadership braces for challenge as shareholders' meeting approaches American City Business Journals
Apr-26-22 08:00AM	Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership GlobeNewswire
Apr-20-22 09:02AM	Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment GlobeNewswire
Apr-12-22 12:45AM	Athira co-founder says departure of Leen Kawas 'casts doubt' on biotech's future American City Business Journals
Apr-05-22 04:04PM	Athira Files Definitive Proxy Statement and Mails Letter to Shareholders GlobeNewswire
Apr-04-22 07:00AM	Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions GlobeNewswire
Mar-31-22 04:26PM	Athira CEO targeted in scathing letter from shareholder American City Business Journals
Mar-30-22 12:12PM	Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future GlobeNewswire
09:51AM	UPDATE 1-Billionaire investor launches board fight at Athira, wants CEO replaced Reuters
09:40AM	Is Athira Pharma, Inc. (ATHA) Outperforming Other Medical Stocks This Year? Zacks
07:30AM	Billionaire investor launches board fight at Athira, wants CEO replaced Reuters
Mar-24-22 04:05PM	Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update GlobeNewswire +5.60%
Mar-21-22 07:05AM	Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors GlobeNewswire
07:00AM	Athira Pharma to Participate in Two Upcoming Investor Conferences GlobeNewswire
Mar-20-22 04:50AM	Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimers Disease at the 2022 AD/PD Congress GlobeNewswire
Mar-18-22 02:39PM	Former Athira CEO Leen Kawas launches biotech investment firm American City Business Journals +8.37%
Mar-17-22 07:00AM	Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022 GlobeNewswire
Mar-14-22 07:00AM	Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimers Disease at AD/PD 2022 Congress GlobeNewswire
Mar-02-22 02:15PM	Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting GlobeNewswire
Feb-22-22 07:05AM	Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting GlobeNewswire
07:00AM	Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease GlobeNewswire
Feb-07-22 06:38PM	Laird Norton Trust Company, Llc Buys iShares National Muni Bond ETF, iShares Core S&P 500 ... GuruFocus.com
Jan-31-22 05:52PM	Athira Pharma appoints new board member American City Business Journals
07:00AM	Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors GlobeNewswire
Jan-25-22 07:00AM	Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies GlobeNewswire
Jan-05-22 07:00AM	Athira Pharma Provides 2022 Pipeline Outlook GlobeNewswire
Dec-13-21 09:47AM	Is the Options Market Predicting a Spike in Athira Pharma (ATHA) Stock? Zacks
04:41AM	What Kind Of Shareholders Own Athira Pharma, Inc. (NASDAQ:ATHA)? Simply Wall St.
Nov-10-21 04:05PM	Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update GlobeNewswire
11:50AM	Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimers Disease at CTAD Conference GlobeNewswire
Nov-08-21 07:00AM	Athira Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Oct-29-21 07:00AM	Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300 GlobeNewswire +7.57%
Oct-25-21 01:38AM	Former Athira CEO addresses controversy and departure in letter to employees American City Business Journals +5.98%
Oct-23-21 02:18PM	(ATHA) Alert: Did You Acquire Athira Before November 2020? Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel GlobeNewswire
Oct-22-21 05:00PM	Athira CEO Resigns After Data Manipulation Firestorm, But Alzheimer's Stock Pops Investor's Business Daily +11.21%
12:31PM	Athira Pharma Stock Climbs on Alzheimer's Test; CEO Resignation TheStreet.com
11:45AM	Why Shares of Athira Pharma Are Climbing Today Motley Fool
08:22AM	Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimers Disease GlobeNewswire
07:36AM	The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs Benzinga
Oct-21-21 05:11PM	Leen Kawas officially out at Athira after investigation finds doctored research American City Business Journals
04:05PM	Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer GlobeNewswire
Sep-29-21 08:05AM	Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimers Disease (CTAD) Conference GlobeNewswire
Sep-20-21 05:57PM	Athira grant application used doctor's credentials without his knowledge American City Business Journals
Sep-17-21 05:50PM	Athira Pharma, Inc. (ATHA) Dips More Than Broader Markets: What You Should Know Zacks
Sep-14-21 06:43AM	We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely Simply Wall St. -5.96%
Aug-25-21 06:17PM	Athira Deadline Alert Newsfile
Aug-24-21 07:45PM	CLASS ACTION UPDATE for ATHA, OTLY and AHCO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
03:33PM	Final Hours for Shareholders to Actively Participate in Athira Pharma, Inc. (ATHA) Class Action: Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
11:00AM	Last Day for Shareholders to Actively Participate in Athira Pharma, Inc. (ATHA) Class Action: Bronstein, Gewirtz & Grossman, LLC Business Wire
10:18AM	DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
09:37AM	ATHA DEADLINE TODAY: Hagens Berman Encourages Athira Pharma (ATHA) Investors with Losses to Contact Firm's Attorneys Now, Lead Plaintiff Deadline Today Newsfile
01:10AM	FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $750,000 to Contact the Firm ACCESSWIRE
Aug-23-21 11:26PM	Athira Pharma, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm GlobeNewswire +6.03%
07:45PM	ATHIRA PHARMA 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA PR Newswire
07:03PM	Athira Deadline Alert Newsfile
02:43PM	Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Athira Pharma, Inc. Investors ATHA Business Wire
02:20PM	ATHA DEADLINE TOMORROW: Hagens Berman Encourages Athira Pharma (ATHA) Investors with Losses to Contact Firms Attorneys Now, August 24th Deadline in Securities Class Action ACCESSWIRE
12:30PM	LEAD PLAINTIFF DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:00PM	DEADLINE ALERT for TEDU and ATHA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:30AM	CLASS ACTION UPDATE for ATHA, CRMD and VIEW: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:00AM	One Day Remaining for Shareholders to Actively Participate in Athira Pharma, Inc. (ATHA) Class Action: Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
11:00AM	Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA) GlobeNewswire
09:11AM	DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
09:10AM	LAWSUITS FILED AGAINST ATHA, PLL and ATVI - Jakubowitz Law Pursues Shareholders Claims ACCESSWIRE
07:30AM	Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimers Disease Summit GlobeNewswire
06:34AM	FINAL DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before Important August 24 Deadline in Securities Class Action - ATHA Newsfile
02:02AM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA) Business Wire
Aug-22-21 06:30PM	ATHIRA PHARMA 48 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA Newsfile
08:27AM	ATHIRA DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their Options GlobeNewswire
08:27AM	Athira Class Action Reminder Newsfile
Aug-21-21 01:57PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA GlobeNewswire
11:51AM	ATHA 3-DAY DEADLINE ALERT: Hagens Berman Encourages Athira Pharma (ATHA) Investors with Losses to Contact Firms Attorneys Before August 24th Deadline in Securities Class Action GlobeNewswire
09:03AM	FINAL NOTICE: Investors with Substantial Losses Have Opportunity to Lead the Athira Pharma, Inc. Class Action Lawsuit - ATHA PR Newswire
Aug-20-21 10:50PM	ATHIRA PHARMA 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA Business Wire
07:10PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ATHA, QFIN and ANVS ACCESSWIRE
06:24PM	Athira Shareholder Notice Newsfile
04:57PM	ATHA FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action ATHA GlobeNewswire
03:00PM	4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
02:14PM	ATHA DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP Important August 24, 2021 Deadline Reminder for Athira Pharma, Inc. Investors GlobeNewswire
01:12PM	ATHA 4-DAY DEADLINE ALERT: Hagens Berman Encourages Athira Pharma (ATHA) Investors with Losses to Contact Firm's Attorneys Before Application Deadline in Securities Fraud Class Action Newsfile
11:45AM	The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athira Pharma, Inc. (ATHA) Investors PR Newswire
11:00AM	ATHA, RKT & REKR Class Action Reminders: Bronstein, Gewirtz & Grossman LLC ACCESSWIRE

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Worthington Mark	General Counsel	Jun 23	Sale	2.69	2,614	7,032	19,097	Jun 24 07:55 PM
MILESON GLENNA	Chief Financial Officer	Jun 23	Sale	2.69	2,614	7,032	109,167	Jun 24 07:53 PM
Litton Mark James	Chief Executive Officer	Jun 23	Sale	2.69	7,960	21,412	128,555	Jun 24 07:51 PM
Lenington Rachel	Chief Operating Officer	Jun 23	Sale	2.69	4,193	11,279	5,807	Jun 24 07:50 PM
CHURCH KEVIN	Executive VP, Research	Jun 23	Sale	2.69	2,614	7,032	57,695	Jun 24 07:25 PM
CHURCH KEVIN	Executive VP, Research	Jun 08	Option Exercise	1.35	2,500	3,375	50,309	Jun 10 05:53 PM
MILESON GLENNA	Chief Financial Officer	Apr 11	Option Exercise	10.64	3,000	31,920	100,060	Apr 12 07:36 PM
Romano Kelly A	Director	Mar 31	Buy	13.11	8,000	104,880	8,315	Apr 01 04:40 PM
CHURCH KEVIN	Executive VP, Research	Feb 18	Option Exercise	1.19	3,152	3,751	47,566	Feb 18 07:38 PM
MILESON GLENNA	Chief Financial Officer	Jan 04	Option Exercise	1.35	6,305	8,512	97,060	Jan 06 05:08 PM
Litton Mark James	Chief Operating Officer	Aug 17	Option Exercise	1.35	50,440	68,094	114,873	Aug 19 05:05 PM
MOEBIUS HANS	Chief Medical Officer	Jul 21	Option Exercise	1.35	28,372	38,302	30,427	Jul 21 04:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience